Recent advances in atopic dermatitis and psoriasis: Genetic background, barrier function, and therapeutic targets

Journal of Dermatological Science

Volumn 78, Issue 2, 2015, Pages 89-94

  Miyagaki, Tomomitsu ^a   Sugaya, Makoto ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMOROLFINE; ANTIFUNGAL AGENT; BRODALUMAB; BUTENAFINE; CASPASE 14; CYCLOSPORIN; DOPAMINE; E 6005; FILAGGRIN; INTERLEUKIN 22; INTERLEUKIN 31; INTERLEUKIN 6 ANTIBODY; INVOLUCRIN; ITRACONAZOLE; IXEKIZUMAB; KETOCONAZOLE; LULICONAZOLE; MESSENGER RNA; METHOTREXATE; PYROGLUTAMIC ACID; RETINOID; SECUKINUMAB; SPHINGOSINE 1 PHOSPHATE; TERBINAFINE; THYMIC STROMAL LYMPHOPOIETIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A;

ATOPIC DERMATITIS; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TARGETING; ECZEMA; ELECTROACUPUNCTURE; EPIDERMIS HYPERPLASIA; GENE; GENETIC ASSOCIATION; HUMAN; IL13 GENE; IN VITRO STUDY; KERATINOCYTE; LOSS OF FUNCTION MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RTEL1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; STAPHYLOCOCCUS AUREUS; STRATUM CORNEUM; ZMIZ1 GENE; ZNF365 GENE; DERMATITIS, ATOPIC; FUNCTIONS OF THE SKIN AND ITS APPENDAGES; GENETICS; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

DERMATITIS, ATOPIC; HUMANS; MOLECULAR TARGETED THERAPY; PSORIASIS; SKIN PHYSIOLOGICAL PHENOMENA;

EID: 84926991490     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2015.02.010     Document Type: Review

References (50)

1. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., Zhao Y., Liao H., Lee S.P., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006, 38:441-446.
2. Guttman-Yassky E., Nograles K.E., Krueger J.G. Contrasting pathogenesis of atopic dermatitis and psoriasis-Part II: Immune cell subsets and therapeutic concepts. J Allergy Clin Immunol 2011, 127:1420-1432.
3. Eyerich K., Pennino D., Scarponi C., Foerster S., Nasorri F., Behrendt H., et al. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol 2009, 123:59-66.
4. Kim B.E., Howell M.D., Guttman-Yassky E., Gilleaudeau P.M., Cardinale I.R., Boguniewicz M., et al. TNF-α downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-α antagonists to improve skin barrier. J Invest Dermatol 2011, 131:1272-1279.
5. Kawasaki H., Nagao K., Kubo A., Hata T., Shimizu A., Mizuno H., et al. Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice. J Allergy Clin Immunol 2012, 129:1538-1546.
6. Sasaki T., Furusyo N., Shiohama A., Takeuchi S., Nakahara T., Uchi H., et al. Filaggrin loss-of-function mutations are not a predisposing factor for atopic dermatitis in an Ishigaki Island under subtropical climate. J Dermatol Sci 2014, 76:10-15.
7. Egawa G., Doi H., Miyachi Y., Kabashima K. PCR-RFLP analysis for S2889X in filaggrin harbors the risk of a typing error. J Dermatol Sci 2013, 69:262-263.
8. Li P., Wu B., Guo B., Zhang X., Li Y., Cheng H., et al. Genetic variants rs2393903 at 10q21.2 and rs6010620 at 20q13.33 are associated with clinical features of atopic dermatitis in the Chinese Han population. J Dermatol Sci 2013, 72:64-66.
9. Tamari M., Saeki H., Hayashi M., Umezawa Y., Ito T., Fukuchi O., et al. An association study of 36 psoriasis susceptibility loci for psoriasis vulgaris and atopic dermatitis in a Japanese population. J Dermatol Sci 2014, 76:156-157.
10. Loiseau N., Obata Y., Moradian S., Sano H., Yoshino S., Aburai K., et al. Altered sphingoid base profiles predict compromised membrane structure and permeability in atopic dermatitis. J Dermatol Sci 2013, 72:296-303.
11. Jung M., Choi J., Lee S.A., Kim H., Hwang J., Choi E.H. Pyrrolidone carboxylic acid levels or caspase-14 expression in the corneocytes of lesional skin correlates with clinical severity, skin barrier function and lesional inflammation in atopic dermatitis. J Dermatol Sci 2014, 76:231-239.
12. Son E.D., Kim H.J., Park T., Shin K., Bae I.H., Lim K.M., et al. Staphylococcus aureus inhibits terminal differentiation of normal human keratinocytes by stimulating interleukin-6 secretion. J Dermatol Sci 2014, 74:64-71.
13. Kakinuma T., Nakamura K., Wakugawa M., Mitsui H., Tada Y., Saeki H., et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001, 107:535-541.
14. Shoda T., Futamura K., Kobayashi F., Saito H., Matsumoto K., Matsuda A. Expression of thymus and activation-regulated chemokine (TARC) by human dermal cells, but not epidermal keratinocytes. J Dermatol Sci 2014, 76:90-95.
15. Gaspar K., Kukova G., Bunemann E., Buhren B.A., Sonkoly E., Szollosi A.G., et al. The chemokine receptor CCR3 participates in tissue remodeling during atopic skin inflammation. J Dermatol Sci 2013, 71:12-21.
16. Kato A., Fujii E., Watanabe T., Takashima Y., Matsushita H., Furuhashi T., et al. Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis. J Dermatol Sci 2014, 74:229-235.
17. Soumelis V., Reche P.A., Kanzler H., Yuan W., Edward G., Homey B., et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002, 3:673-680.
18. Hau C.S., Kanda N., Watanabe S. Suppressive effects of antimycotics on thymic stromal lymphopoietin production in human keratinocytes. J Dermatol Sci 2013, 71:174-183.
19. Sakai T., Hatano Y., Zhang W., Fujiwara S. Defective maintenance of pH of stratum corneum is correlated with preferential emergence and exacerbation of atopic-dermatitis-like dermatitis in flaky-tail mice. J Dermatol Sci 2014, 74:222-228.
20. Andoh T., Kuraishi Y. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP. J Dermatol Sci 2014, 76:206-213.
21. Jung D.L., Lee S.D., Choi I.H., Na H.S., Hong S.U. Effects of electroacupuncture on capsaicin-induced model of atopic dermatitis in rats. J Dermatol Sci 2014, 74:23-30.
22. Mori T., Kabashima K., Fukamachi S., Kuroda E., Sakabe J., Kobayashi M., et al. D1-like dopamine receptors antagonist inhibits cutaneous immune reactions mediated by Th2 and mast cells. J Dermatol Sci 2013, 71:37-44.
23. Bowcock A.M. The genetics of psoriasis and autoimmunity. Annu Rev Genomics Hum Genet 2005, 6:93-122.
24. Tsoi L.C., Spain S.L., Knight J., Ellinghaus E., Stuart P.E., Capon F., et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 2012, 44:1341-1348.
25. Saeki H., Hirota T., Nakagawa H., Tsunemi Y., Kato T., Shibata S., et al. Genetic polymorphisms in the IL22 gene are associated with psoriasis vulgaris in a Japanese population. J Dermatol Sci 2013, 71:148-150.
26. Zhou X., Xu L.D., Li Y.Z. The association of polymorphisms of the vitamin D receptor gene with psoriasis in the Han population of northeastern China. J Dermatol Sci 2014, 73:63-66.
27. Hayashi M., Hirota T., Saeki H., Nakagawa H., Ishiuji Y., Matsuzaki H., et al. Genetic polymorphism in the TRAF3IP2 gene is associated with psoriasis vulgaris in a Japanese population. J Dermatol Sci 2014, 73:264-265.
28. Eirís N., González-Lara L., Santos-Juanes J., Queiro R., Coto E., Coto-Segura P. Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus. J Dermatol Sci 2014, 75:167-172.
29. Yin X.Y., Cheng H., Wang W.J., Wang W.J., Fu H.Y., Liu L.H., et al. TNIP1/ANXA6 and CSMD1 variants interacting with cigarette smoking, alcohol intake affect risk of psoriasis. J Dermatol Sci 2013, 70:94-98.
30. Sugiura K. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants. J Dermatol Sci 2014, 74:187-192.
31. Li X., Chen M., Fu X., Zhang Q., Wang Z., Yu G., et al. Mutation analysis of the IL36RN gene in Chinese patients with generalized pustular psoriasis with/without psoriasis vulgaris. J Dermatol Sci 2014, 76:132-138.
32. Hayashi M., Nakayama T., Hirota T., Saeki H., Nobeyama Y., Ito T., et al. Novel IL36RN gene mutation revealed by analysis of 8 Japanese patients with generalized pustular psoriasis. J Dermatol Sci 2014, 76:267-269.
33. Hou R., Yin G., An P., Wang C., Liu R., Yang Y., et al. DNA methylation of dermal MSCs in psoriasis: identification of epigenetically dysregulated genes. J Dermatol Sci 2013, 72:103-109.
34. Chen J.Q., Man X.Y., Li W., Zhou J., Landeck L., Cai S.Q., et al. Regulation of involucrin in psoriatic epidermal keratinocytes: the roles of ERK1/2 and GSK-3β. Cell Biochem Biophys 2013, 66:523-528.
35. Dugu L., Nakahara T., Wu Z., Uchi H., Liu M., Hirano K., et al. Neuronatin is related to keratinocyte differentiation by up-regulating involucrin. J Dermatol Sci 2014, 73:225-231.
36. Moniaga C.S., Egawa G., Miyachi Y., Kabashima K. Calcipotriol modulates IL-22 receptor expression and keratinocyte proliferation in IL-22-induced epidermal hyperplasia. J Dermatol Sci 2013, 71:76-77.
37. Zhao S., Chen C., Liu S., Zeng W., Su J., Wu L., et al. CD147 promotes MTX resistance by immune cells through up-regulating ABCG2 expression and function. J Dermatol Sci 2013, 70:182-189.
38. Hoffmann J.H., Knoop C., Enk A.H., Hadaschik E.N. Baseline anti-dsDNA concentrations and previous treatments predict response to adalimumab and etanercept: a retrospective investigation of 146 psoriasis patients. J Dermatol Sci 2014, 76:180-185.
39. Sano S., Chan K.S., Carbajal S., Clifford J., Peavey M., Kiguchi K., et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005, 11:43-49.
40. Takaishi M., Nakajima K., Ouyang W., Sano S. Psoriasis-like skin lesions are dependent on IL-23 but develop in the absence of IL-22 in a model mouse. J Dermatol Sci 2014, 73:261-264.
41. Osamu N., Hirotaka N., Koji S., Kenji T. Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study. J Dermatol Sci 2014, 75:201-204.
42. Hemmerle T., Zgraggen S., Matasci M., Halin C., Detmar M., Neri D. Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation. J Dermatol Sci 2014, 76:96-103.
43. Sugiyama H., Gyulai R., Toichi E., Garaczi E., Shimada S., Stevens S.R., et al. Dysfunctional blood and target tissue CD4+CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005, 174:164-173.
44. Chen L., Wu J., Ren W., Yang X., Shen Z. c-Jun N-terminal kinase (JNK)-phospho-c-JUN (ser63/73) pathway is essential for FOXP3 nuclear translocation in psoriasis. J Dermatol Sci 2013, 69:114-121.
45. Peters J.H., Tjabringa G.S., Fasse E., de Oliveira V.L., Schalkwijk J., Koenen H.J., et al. Co-culture of healthy human keratinocytes and T-cells promotes keratinocyte chemokine production and ROR (t-positive IL-17 producing T-cell populations. J Dermatol Sci 2013, 69:44-53.
46. Tarutani M., Nakajima K., Takaishi M., Ohko K., Sano S. Epidermal hyperplasia induced by Raf-MAPK signaling requires Stat3 activation. J Dermatol Sci 2013, 72:110-115.
47. Schaper K., Dickhaut J., Japtok L., Kietzmann M., Mischke R., Kleuser B., et al. Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis. J Dermatol Sci 2013, 71:29-36.
48. Suzuki T., Hirakawa S., Shimauchi T., Ito T., Sakabe J., Detmar M., et al. VEGF-A promotes IL-17A-producing γδT cell accumulation in mouse skin and serves as a chemotactic factor for plasmacytoid dendritic cells. J Dermatol Sci 2014, 74:116-124.
49. Diaconu D., Fritz Y., Dawes S.M., Loyd C.M., Ward N.L. VEGF-Trap decreases CD4+ T cells, Th17 cytokines improving psoriasis-like skin inflammation in KC-Tie2 mice. J Dermatol Sci 2013, 72:322-325.
50. Koga Y., Jinnin M., Ichihara A., Fujisawa A., Moriya C., Sakai K., et al. Analysis of expression pattern of serum microRNA levels in patients with psoriasis. J Dermatol Sci 2014, 74:170-171.